Pulmonx/$LUNG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pulmonx
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Ticker
$LUNG
Sector
Primary listing
Employees
296
Headquarters
Website
Pulmonx Metrics
BasicAdvanced
$54M
-
-$1.33
0.11
-
Price and volume
Market cap
$54M
Beta
0.11
52-week high
$7.05
52-week low
$1.13
Average daily volume
671K
Financial strength
Current ratio
5.069
Quick ratio
4.109
Long term debt to equity
101.722
Total debt to equity
104.154
Interest coverage (TTM)
-17.01%
Profitability
EBITDA (TTM)
-52.566
Gross margin (TTM)
74.19%
Net profit margin (TTM)
-59.67%
Operating margin (TTM)
-59.30%
Effective tax rate (TTM)
-1.17%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-22.96%
Return on equity (TTM)
-77.19%
Valuation
Price to revenue (TTM)
0.575
Price to book
0.99
Price to tangible book (TTM)
1.02
Price to free cash flow (TTM)
-1.586
Free cash flow yield (TTM)
-63.04%
Free cash flow per share (TTM)
-0.807
Growth
Revenue change (TTM)
8.01%
Earnings per share change (TTM)
-7.95%
3-year revenue growth (CAGR)
19.03%
3-year earnings per share growth (CAGR)
-5.81%
What the Analysts think about Pulmonx
Analyst ratings (Buy, Hold, Sell) for Pulmonx stock.
Pulmonx Financial Performance
Revenues and expenses
Pulmonx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pulmonx stock?
Pulmonx (LUNG) has a market cap of $54M as of April 02, 2026.
What is the P/E ratio for Pulmonx stock?
The price to earnings (P/E) ratio for Pulmonx (LUNG) stock is 0 as of April 02, 2026.
Does Pulmonx stock pay dividends?
No, Pulmonx (LUNG) stock does not pay dividends to its shareholders as of April 02, 2026.
When is the next Pulmonx dividend payment date?
Pulmonx (LUNG) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulmonx?
Pulmonx (LUNG) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.